Business Wire

PCAST Working Group, Co-Led by PSMF Founder Joe Kiani, Releases Report on Transforming Patient Safety

8.9.2023 04:43:00 EEST | Business Wire | Press release

Share

The President’s Council of Advisors on Science and Technology (PCAST) released its findings and recommendations on patient safety in a report to U.S. President Joe Biden. Titled “A Transformational Effort on Patient Safety,” the report also outlines the many ways that “patient safety is an urgent national public health issue.” The distinguished PCAST Working Group on Patient Safety is co-led by the founder of the Patient Safety Movement Foundation, Joe Kiani, and Microsoft’s Chief Scientific Officer, Eric Horvitz.

The PCAST report to the Biden-Harris administration pointed out that according to recent data, “Medicare patients suffer an adverse event in one out of four hospitalizations, and one third of those adverse events are serious, including catastrophic outcomes,” and that “adverse outcomes disproportionately impact people from groups historically experiencing social marginalization, widening gaps in healthcare disparities.”

“Preventable medical errors take hundreds of thousands of lives each year. I am optimistic that these recommendations will help fast-track solving this critical problem that destroys so many lives,” said Joe Kiani, co-leader of the PCAST Working Group on Patient Safety. “It was an honor to work with such a distinguished cohort of fellow PCAST committee members on what we believe is an urgent mission, and I am grateful for everyone’s contributions. I know President Biden has been waiting for this report. He is our country’s biggest patient advocate and cares deeply about the very real suffering that happens every day across the U.S. healthcare systems due to medical errors.”

“This is a major milestone in healthcare safety in the United States, and if implemented, we believe it will influence and improve patient safety and healthcare worker safety around the world. Since our inception, we understood that for long-lasting change to happen, it would require direction from the highest levels of government. These recommendations could not have come at a better time because WHO’s World Patient Safety Day is on September 17th,” said Dr. Michael Ramsay, CEO of the Patient Safety Movement Foundation.

The report acknowledges that despite significant efforts made by many healthcare workers and organizations to reduce preventable medical errors by implementing evidence-based safety protocols, nationwide implementation of many of these known solutions has lagged. The report then outlines four recommendations to “advance health equity, improve the nation’s health and well-being, and avert suffering and death for hundreds of thousands of Americans each year.” The recommendations are as follows:

Recommendation 1: Establish and Maintain Federal Leadership for the Improvement of Patient Safety as a National Priority.

1.A Appoint a Patient Safety Coordinator Reporting to the President on Efforts to Transform Patient Safety Among All Relevant Government Agencies.
1.B Establish a Multidisciplinary National Patient Safety Team (NPST) and Ensure Inclusion of Persons from Populations Most Affected.

Recommendation 2: Ensure That Patients Receive Evidence-Based Practices for Preventing Harm and Addressing Risks.

2.A Identify and Address High-Priority Harms and Promote Patient Safety Though Incentivizing the Adoption of Evidence-Based Solutions and Requiring Annual Public Reporting Immediately and Quarterly Public Reporting Within 5 Years.
2.B Create a Learning Ecosystem and Shared Accountability System to Ensure That Evidence-Based Practices are Implemented and Goals for Reduced Harms and Risks of Harm for Every American are Realized.
2.C Advance Interoperability of Healthcare Data and Assure Access to the Tracking of Harms and Use of Evidence-Based Solutions.
2.D Improve Safety for All Healthcare Workers and Their Patients Through Supporting a Just Culture of Patient and Clinician Safety in Healthcare Systems.

Recommendation 3: Partner with Patients and Reduce Disparities in Medical Errors and Adverse Outcomes.

3.A Implement a “Whole of Society Approach” in the Transformational Effort on Patient Safety.
3.B Improve Data and Transparency to Reduce Disparities.

Recommendation 4: Accelerate Research and Deployment of Practices, Technologies, and Exemplar Systems of Safe Care.

4.A Develop a National Patient Safety Research Agenda.
4.B Harness Revolutionary Advances in Information Technologies.
4.C Develop Federal Healthcare Delivery Systems’ Capacities and Showcase Results as Exemplars for Safer Healthcare.

PCAST is a federal advisory committee appointed by the U.S. president to augment the science and technology advice available to him. PCAST consists of 28 of the nation’s thought leaders, selected for their distinguished service and accomplishments in academia, government, and the private sector. Joe Kiani, who founded the Patient Safety Movement Foundation (PSMF) in 2012 and served for many years as its first chair, was appointed to PCAST in September 2021. Also serving with Kiani and Horvitz in the PCAST patient safety working group are:

  • Donald Berwick, MD, Patient safety expert, CMS, Institute for Healthcare Improvement
  • Lisa Cooper, Johns Hopkins University
  • Sue Desmond-Hellmann, Former CEO, Gates Foundation, Former Chancellor UCSF
  • Christopher Hart, Safety systems expert, National Transportation Safety Board
  • Harlan Krumholz, MD, Outcomes research pioneer, Yale University
  • Julie Morath, RN, Patient safety expert, Hospital Quality Institute
  • Peter Pronovost, MD, Patient safety expert, University Hospitals Cleveland Medical Center
  • Sue Sheridan, Patient advocate, Patients for Patient Safety

ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye